Analysts predict transformative biotherapies to lead future cancer treatment breakthroughs, with Oncolytics poised for key role.
Analysts predict transformative biotherapies to lead future cancer treatment breakthroughs, with Oncolytics poised for key role.
Dual GLP-1 and GIP receptor agonist VK2735 moves into pivotal trials targeting robust weight loss and glycemic control …
Novel agent ENT-03 demonstrates promising metabolic improvements and safety in first-in-human study, setting stage for further development in …
CEO Lamballe highlights strategic advances, upcoming trial readouts, and expansion of microbiome ecosystem therapies pipeline.
Phase 3 trial data show promising metabolic improvements and durable weight reduction, expanding potential treatment options for millions.
Sustained-release axitinib hydrogel shows promising efficacy and safety in wet age-related macular degeneration and diabetic retinopathy, setting foundation …
First biologic approved for this rare autoimmune blistering skin disease; pivotal trial data drive swift Priority Review.
Cycle Pharmaceuticals’ CEO calls approval “a defining moment for patients, physicians and science—proving unmet metabolic needs can be …
New clinical findings support dapiglutide’s potential as first-in-class injectable therapy; CEO touts “milestone in multi-receptor peptide innovation”.
Commercial partnership targets scalability, 24/7 PET imaging product access, and future expansion for next-gen cancer diagnostics.
